Skinbiotherapeutics Share Discussion Threads

[owenmo] 22/1/2018 11:01

Jes*s, he's back and with a vengeance! Save and protect us.

[bobalot] 21/1/2018 16:47

here is a recap from a November post regarding human trials starting in Q2/2018.

Here is a very good summary of exactly where the business development is at --- THE DEVELOPMENT OF SKIN RELATED PRODUCTS IS DEVELOPING FAST WITH NEW PRODUCTS IN THE OFFERING.


SkinBioTherapeutics technology gets double green light - next stop human studies


Researchers at Charles River Laboratories assessed for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells)

The company's first product will be a skincare cosmetic

SkinBioTherapeutics PLC (LON:SBTX) said its SkinBiotix technology has passed two additional and final toxicity tests, meaning it is safe to use in the company's three target markets.

Researchers at Charles River Laboratories assessed for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells).

Prior to that, SkinBiotix was found not to be cytotoxic, which in layman terms meant it didn't kill cells it came in contact with.

Focusing on efficacy

"Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focusing on further proving its efficacy, said Dr Catherine O'Neill, chief executive of SkinBioTherapeutics.

The company is focused on developing products and treatments that effect the portion of the human microbiome that resides on the skin.

This is a mix of bacteria, yeasts, and parasites that live on the body's biggest organ. Sounds gross, but this microbial ecosystem is thought to be key to skin health.

Based on the work of CEO Oâ€â;„¢Neill at Manchester University, the SkinBiotix platform is protected by three patent families and 18 patent applications.

It is also supported by a host of peer-reviewed academic publications and has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.

As mentioned above, the firm is developing three products that manage, protect and restore the body outer layer.

First cab off the rank

First cab off the rank will be the company cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.

The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes.

Human trials

Earlier this week SkinBioTherapeutics said it expects a study in people of a cosmetic skin care cream next year to be the start of serious commercialisation talks.

Tentative discussions have already begun, said CEO Neill, but human data is crucial to the process.

In the release Thursday, the company said it was confident of human studies getting underway next year.

www.proactiveinvestors.co.uk/companies/news/186987/skinbiotherapeutics-technology-gets-double-green-light-next-stop-human-studies-186987.html

[bobalot] 21/1/2018 16:19

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain.

SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

[bobalot] 21/1/2018 16:16

SkinBioTherapeutics (SBTX) - SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.

The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.

SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas Skin BioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.

[jamgr0] 20/1/2018 14:36

Thanks Parob

[parob] 20/1/2018 07:53

JamgrO

From Nov 2017



The firm is developing three products that manage, protect and restore the body’s outer layer.

First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.

[bobalot] 20/1/2018 00:03

In articles and RNS's....look them up and DYOR.

[jamgr0] 19/1/2018 12:17

Bobalot - where did you manage to find that info? I knew they were scheduled for 2018 with the trial designs already in place but must have missed that nugget of info

[rafboy] 19/1/2018 09:14

Thanks again, will be interesting to see if they are brought forward.

[bobalot] 19/1/2018 09:06

The human trials were planned to start in Q2. Which means from April onwards.

[rafboy] 19/1/2018 08:43

Thanks bobalot, I knew about the duration but the start date is what I am really interested in. I agree these will be inflexion points.

[bobalot] 19/1/2018 08:33

Possibly from April..it will only take a month then the company hand-over to a commercial partner for product registration and commercialisation.

And those activities are the inflexion points when the share price should takeoff imo.

[rafboy] 18/1/2018 15:49

If possible can someone obtain an approximation of when the human trials will start. Thanks.

[rafboy] 18/1/2018 15:12

Dr David Moyes has done well after leaving Everton!

[ny boy] 18/1/2018 13:40

One would have thought a better venue would have been in London, I don’t travel well up north in the winter😉

[parob] 12/1/2018 20:57

SkinBioTherapeutics Retweeted

Alice Vickers‏ @AliceVickers5

@KCL_IF will be exploring 'Innovations in the Microbiome' with Prof @timspector, Dr Penny Wilson (@innovateuk), Dr Catherine O'Neil (@SkinBioT) and Dr Judith Fernandez-Piquer (@Unilever) on 21st Feb. Tickets available here



Agenda:
Registration - 6:00-6:30pm

Introduction from Innovation Forum- 6:30-6:35pm

Opening Keynote - 6:35-6:45pm
Dr Penny Wilson - Senior Specialist in AMR, Vaccines and Global Health at Innovate UK
Advances in the Microbiome - 6:45-7:45pm
Prof Tim Spector - Professor of Genetic Epidemiology, Director of TwinsUK at King's College London & Author
Dr Catherine O'Neill - CEO of SkinBioTherapeutics
Dr David Moyes - Lecturer in Host-Microbiome Interactions, King's College London
Dr Judith Fernandez-Piquer - Scientist at the Safety & Environmental Assurance Centre, Unilever

[elrico] 12/1/2018 19:36

It depends if you need to sit an interview in Liverpool.

[asterix96] 12/1/2018 16:45

elrico - How long will it take us southerners to get a visa for Manchester?

[elrico] 12/1/2018 16:08

@ 7 miles from kennel, I guess you're correct. Btw, anyone interested in putting faces to usernames, inbox me. Just don't ask me to wear a rose. I suspect most PI's are southerly and fearful of venturing to Madchester.

[luminoso] 12/1/2018 15:35

I'd have thought you could walk there, elrico !

[elrico] 12/1/2018 14:04

Parking is a tad steep.

Dear Elric,

Thank you for registering to the event.

It is a pleasure to welcome you as a delegate to the Shares Investor Evening which will take place at the Macdonald Manchester Hotel on Tuesday 20 February 2018.

Please PRINT and bring this email to the Investor Evening delegate registration desk on the day as we will scan your personal barcode. Alternatively you can show us your barcode from your smart phone or tablet.

Registration commences at 17:45. Tea/coffee will be served from 17:45 to 18:15. Presentations will start at 18:15 sharp and finish at 20:30. They will be followed by a drinks reception.

Venue details:
Macdonald Manchester Hotel
Meeting Room 11
London Road
Manchester
M1 2PG

Transport:
0.3 miles from Manchester Picadilly Station
10.5 miles from Manchester Airport
If traveling by car please use M1 2AD which will direct you the hotel’s car park on Berry Street. Please note the fee to park at the hotel will be £15.00.

[elrico] 12/1/2018 13:57

I've registered.

[parob] 12/1/2018 07:56

Shares Investor Evening (Manchester) - 20 Feb 2018



Companies presenting:

SkinBioTherapeutics (SBTX) - SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.

The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.

SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas Skin BioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.

[rafboy] 05/1/2018 15:50

Interesting year ahead. Glad I topped up when I did.

[parob] 05/1/2018 14:16

SkinBioTherapeutics‏ tweet just now:

"Microbiome Clinical Studies Loom Large In 2018" - very interesting article by @ScripJohnD about recent developments in the #microbiome field and what to expect in 2018. @PharmaScrip